When compared to individuals taking DPP4 inhibitors, the GLP-1 group showed a recurrence risk of 14.4%, while the DPP4 inhibitor group had a risk of 23.3%
Early responses occur within minutes via bradykinin-mediated activation of G protein-coupled receptors, while late protection develops 1224 h later through upregulation of endothelial antioxidant enzymes [213]
This superior efficacy helped it achieve global sales of ~US$16.4bn in 2024 (Mounjaro ~US$11.5bn and Zepbound ~US$4.9bn), rivalling semaglutide and completely overshadowing the sales of historical GLP-1s, such as exenatide, liraglutide and dulaglutide [FIGURE TWO]
M.Vzquez-CarradaM.Uribe-RamrezD.Matuz-MaresD
This work was supported by grants from the Fundacin Rioja Salud (Gobierno de La Rioja, Spain) to JGP and co-funded by the ERDF (European Regional Development Fund), the ESF (European Social Fund), and a donation from Muebles Guerra (La Rioja, Spain
GHK-Cu skin improvements require patience